×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VSTM – verastem, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VSTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
04:11 am
vstm
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
Medium
Report
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
3/4
09:02 pm
vstm
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
07:23 pm
vstm
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/4
06:37 pm
vstm
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
Medium
Report
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
3/4
06:37 pm
vstm
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
04:01 pm
vstm
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
2/26
09:35 am
vstm
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
Low
Report
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
2/19
10:01 am
vstm
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
Low
Report
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/4
04:16 pm
vstm
Form 8-K Verastem, Inc. For: Mar 04
Medium
Report
Form 8-K Verastem, Inc. For: Mar 04
3/4
04:06 pm
vstm
Form 10-K Verastem, Inc. For: Dec 31
Medium
Report
Form 10-K Verastem, Inc. For: Dec 31
2/17
09:43 pm
vstm
Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SCHEDULE 13G Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
2/17
04:35 pm
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Point72 Asset Management, L.P.
2/17
08:54 am
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
Low
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: RTW INVESTMENTS, LP
2/17
06:49 am
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
Low
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
2/13
05:09 pm
vstm
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Nantahala Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Nantahala Capital Management, LLC
2/5
04:11 pm
vstm
Form 4 Verastem, Inc. For: Feb 04 Filed by: Paterson Dan
Medium
Report
Form 4 Verastem, Inc. For: Feb 04 Filed by: Paterson Dan
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
59.4%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
TOP News Decliners
4/27
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
-51.4%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: